Dacomitinib and its Impurities
Dacomitinib (trade name Vizimpro) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Reference standards of Dacomitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
1-(4-((3-Chloro-4-fluorocyclohexyl)amino)-7-methoxyquinazolin-6-yl)-5-hydroxypyrrolidin-2-one
1-(4-((3-Chloro-4-fluorocyclohexyl)amino)-7-methoxyquinazolin-6-yl)-5-hydroxypyrrolidin-2-one
Catalogue No.:PA 04 2191000
CAS :
2190490-31-2
Molecular Formula : C19H16ClFN4O3
Molecular Weight : 402.81
(E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
(E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
Catalogue No.:PA 04 2191003
CAS :
NA
Molecular Formula : C24H24ClFN6O3
Molecular Weight : 498.94
3-((3-Chloro-4-fluorophenyl)amino)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)butanamide
3-((3-Chloro-4-fluorophenyl)amino)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)butanamide
Catalogue No.:PA 04 2191004
CAS :
NA
Molecular Formula : C30H30Cl2F2N6O2
Molecular Weight : 615.51
N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)amino)-4-(piperidin-1-yl)butanamide
N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)amino)-4-(piperidin-1-yl)butanamide
Catalogue No.:PA 04 2191005
CAS :
NA
Molecular Formula : C39H37Cl2F2N9O3
Molecular Weight : 788.68
